Specifically, the FDA approved Omvoh to treat moderately to ... Bayer is vying for a third indication for its Nubeqa (darolutamide) in China, this time for its use in combination with androgen ...

which developed Nubeqa in collaboration with Finland's Orion. The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive ...

Enhertu was given accelerated approval for this indication by the ... oncology player is being spearheaded by prostate cancer drug Nubeqa (darolutamide), which it thinks could become a €3 ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for moderate to ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.